Abstract:Abstract Background: Colorectal cancer (CRC) is one of the most prevalent and deadly cancers in the world. The development of improved and robust biomarkers to enable screening, surveillance, and early detection of CRC continues to be a challenge. Patients with colorectal adenoma are at higher risk of developing colon cancer; however, noninvasive methods to identify these patients are still on demand. The aim of this study was to identify biomarkers of CRC disease progression by using metabolomic profiling of human serum samples in a multistep approach. Methods: We performed global metabolomic profiling on 30 human serum samples from patients with colorectal adenoma, 30 CRC patients and 30 healthy controls who were matched by age, gender and ethnicity. For validation, we measured the three top differentially expressed metabolites in an additional set of 50 adenoma, 50 CRC and 50 healthy controls. Results: Global biochemical profiles of 404 metabolites were detected, with 301 metabolites remaining after quality control procedures. In discovery phase, 50 metabolites had differential levels between colorectal adenoma, CRC and controls (P for trend <0.05), with 19 metabolites showing increased levels in CRC and adenoma in comparison to controls and 31 metabolites with decreased levels. Further exploratory analyses of these metabolites showed a key role for metabolic pathways involving urea cycle, caffeine and galactose metabolism as associated with CRC progression. The top 3 differentially expressed metabolites (Xanthine, Hypoxanthine and D-mannose) were selected for validation. Consistent with the discovery phase, CRC cases and adenoma had lower levels of Xanthine than controls (mean ± SD; 9.95 ±0.92 mg/ml vs 10.63±0.97 mg/ml; P<0.001 and 9.87±0.75 vs 10.63±0.97 mg/ml; P<0.001). The same trend was observed for Hypoxanthine (mean ± SD; 10.72 ±0.62 mg/ml vs 12.29±1.60; P<0.001 and 10.71±0.61 vs 12.29±1.60 mg/ml; P <0.001) whereas higher levels of D-mannose where observed in both CRC cases and adenoma when compared to controls (3.32±0.58 mg/ml vs 2.32 ±0.90mg/ml; P<0.001 and 3.32±0.58 mg/ml vs 2.32 ±0.90mg/ml; P<0.001). Using the median value of controls as a cut-off point, 94% of the adenoma and CRC cases showed low levels of Xanthine (Odds Ratio (OR) = 10.47, 95% confidence interval (CI) = 2.63-41.63 for adenoma; OR = 38.76 and 95% CI = 6.58-228.51 for CRC). For Hypoxanthine, 90% of the adenoma and CRC cases showed low levels (OR = 6.50 and 95% CI = 1.98–21.24 for adenoma; OR = 11.19 and 95% CI = 3.28-38.21 for CRC). For D-Mannose, all adenoma cases had high levels (OR is not available due to 0 count) and 92% of CRC cases (OR = 15.99, 95% Ci = 4.07-62.88, P< 0.001) had high levels of D-Mannose, compared to 50% of controls having high levels of D-Mannose. Conclusions: Our results suggest the potential utility of the identified metabolites as new valuable biomarkers for early detection of CRC. Citation Format: Beatriz Sanchez-Espiridion, Lindsey White, Lopa Mishra, Gottumukkala S. Raju, Scott Kopetz, Jian Gu, Yuanquing Ye, Xifeng Wu, Dong Liang. Global and targeted metabolomic profiling of colorectal cancer progression. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 8.

Urine-NMR metabolomics for screening of advanced colorectal adenoma and early stage colorectal cancer

392P Integrating Fragmentomic Features for Non-Invasive Early Detection of Colorectal Advanced Adenoma and Adenocarcinoma

Screening for Early Gastric Cancer Using a Noninvasive Urine Metabolomics Approach

Urinary metabonomic study on colorectal cancer.

Urinary 1H-NMR Metabolic Signature in Subjects Undergoing Colonoscopy for Colon Cancer Diagnosis

A 5-Hydroxymethylcytosine-based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: the METHOD-2 Study

Integrated analysis of colorectal neoplasia tissue and gut microbiome associated serum metabolites for diagnosis of early-stage CRC and advanced adenoma.

Distinct Urinary Metabolic Biomarkers of Human Colorectal Cancer

Metabolomic Comparison of Patients With Colorectal Cancer at Different Anticancer Treatment Stages

NMR‐based metabolomics combined with metabolic pathway analysis reveals metabolic heterogeneity of colorectal cancer tissue at different anatomical locations and stages

Circulating Bacterial DNA As a Tool Towards Noninvasive Biomarkers for Colorectal Adenocarcinoma and Adenoma.

Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery.

Distinct urinary metabolic profile of human colorectal cancer.

Ultra-High Performance Liquid Chromatography–Mass Spectrometry for the Metabolomic Analysis of Urine in Colorectal Cancer

Profiling the metabolic disorder and detection of colorectal cancer based on targeted amino acids metabolomics

Abstract 8: Global and Targeted Metabolomic Profiling of Colorectal Cancer Progression

Development of a urine-based metabolomics approach for multi-cancer screening and tumor origin prediction

Untargeted GC-MS-Based Metabolomics for Early Detection of Colorectal Cancer

Metabolic profiling analysis for clinical urine of colorectal cancer

Abstract 3346: Evaluation of a serum-based test integrating tumor tissue and gut microbiome derived metabolites for diagnosis of advanced colorectal adenoma

Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers